As such, immune checkpoint blockade (ICB) therapy using immune checkpoint inhibitors (ICIs) to block the PD-1 and PD-L1 axes and interrupt their interaction for cancer immunotherapy has been developed as a new milestone, and some clinical trials have achieved promising results [1,92,93]. This evidence concerns the gene PDCD1 and cancer.